Antitachycardia pacing: A worthy cause?
作者信息
Ho Gordon, Birgersdotter-Green Ulrika
机构信息
Department of Medicine, Division of Cardiology Cardiac Electrophysiology, Cardiovascular Institute, University of California San Diego, San Diego, California, USA.
出版信息
J Cardiovasc Electrophysiol. 2020 Oct;31(10):2727-2729. doi: 10.1111/jce.14684. Epub 2020 Jul 30.
Abstract
摘要
相似文献
1
Antitachycardia pacing: A worthy cause?
J Cardiovasc Electrophysiol. 2020 Oct;31(10):2727-2729. doi: 10.1111/jce.14684. Epub 2020 Jul 30.
2
Antitachycardia pacing therapy for the successful treatment of lead fracture.
J Cardiovasc Electrophysiol. 2015 Feb;26(2):228-9. doi: 10.1111/jce.12577. Epub 2014 Nov 26.
3
Marked attenuation of shock burden by the use of antitachycardia pacing therapy in a patient with an implanted cardioverter-defibrillator.
Tex Heart Inst J. 2012;39(4):568-70.
4
Ventricular pacing induced ventricular tachycardia in patients with implantable cardioverter defibrillators.
Pacing Clin Electrophysiol. 1995 Mar;18(3 Pt 1):486-91. doi: 10.1111/j.1540-8159.1995.tb02551.x.
5
Antitachycardia pacing for ventricular tachycardia using implantable cardioverter defibrillators:
Pacing Clin Electrophysiol. 2004 Sep;27(9):1292-305. doi: 10.1111/j.1540-8159.2004.00622.x.
6
Experience with three different third-generation cardioverter-defibrillators in patients with coronary artery disease or cardiomyopathy.
Am J Cardiol. 1993 Aug 1;72(3):301-4. doi: 10.1016/0002-9149(93)90676-4.
7
Clinical experience with antitachycardia pacing and improved detection algorithms in a new implantable cardioverter-defibrillator.
J Am Coll Cardiol. 1993 Mar 15;21(4):885-94. doi: 10.1016/0735-1097(93)90343-y.
8
Comparison of novel intrinsic versus conventional antitachycardia pacing for ventricular tachycardia among implantable cardioverter-defibrillator recipients.
J Cardiovasc Electrophysiol. 2024 Apr;35(4):821-831. doi: 10.1111/jce.16232. Epub 2024 Feb 29.
9
Inducible ventricular tachycardia due to dermatomyositis-related cardiomyopathy in the era of implantable cardioverter-defibrillator therapy.
Circulation. 2012 Feb 21;125(7):967-9. doi: 10.1161/CIRCULATIONAHA.111.049882.
10
Incidence and relevance of nonreentrant monomorphic ventricular tachycardia in patients with frequent implantable cardioverter defibrillator interventions.
J Interv Card Electrophysiol. 2015 Mar;42(2):151-60. doi: 10.1007/s10840-015-9973-8. Epub 2015 Jan 27.
引用本文的文献
1
Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: .
Front Cardiovasc Med. 2025 Feb 19;12:1539125. doi: 10.3389/fcvm.2025.1539125. eCollection 2025.
2
Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database.
J Int Med Res. 2024 Mar;52(3):3000605241238993. doi: 10.1177/03000605241238077.
3
Device-Related Complications and Inappropriate Therapies Among Subcutaneous vs. Transvenous Implantable Defibrillator Recipients: Insight Monaldi Rhythm Registry.
Front Cardiovasc Med. 2022 May 16;9:879918. doi: 10.3389/fcvm.2022.879918. eCollection 2022.
本文引用的文献
1
Characteristics of ventricular tachyarrhythmias and their susceptibility to antitachycardia pacing termination in patients with ischemic and nonischemic cardiomyopathy: A patient-level meta-analysis of three large clinical trials.
J Cardiovasc Electrophysiol. 2020 Oct;31(10):2720-2726. doi: 10.1111/jce.14688. Epub 2020 Jul 28.
2
Risk stratification in patients with nonischemic cardiomyopathy and ventricular arrhythmias based on quantification of intramural delayed enhancement on cardiac magnetic resonance imaging.
J Cardiovasc Electrophysiol. 2020 Jul;31(7):1762-1769. doi: 10.1111/jce.14514. Epub 2020 May 18.
3
Understanding Outcomes with the EMBLEM S-ICD in Primary Prevention Patients with Low EF Study (UNTOUCHED): Clinical characteristics and perioperative results.
Heart Rhythm. 2019 Nov;16(11):1636-1644. doi: 10.1016/j.hrthm.2019.04.048. Epub 2019 May 10.
4
Ventricular Tachycardia Ablation in Nonischemic Cardiomyopathy.
JACC Clin Electrophysiol. 2018 Sep;4(9):1123-1140. doi: 10.1016/j.jacep.2018.06.014. Epub 2018 Aug 29.
5
Myocardial Fibrosis Assessment by LGE Is a Powerful Predictor of Ventricular Tachyarrhythmias in Ischemic and Nonischemic LV Dysfunction: A Meta-Analysis.
JACC Cardiovasc Imaging. 2016 Sep;9(9):1046-1055. doi: 10.1016/j.jcmg.2016.01.033. Epub 2016 Jul 20.
6
Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results.
Heart Rhythm. 2015 May;12(5):926-36. doi: 10.1016/j.hrthm.2015.01.017. Epub 2015 Jan 28.
7
Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
Heart Rhythm. 2015 Mar;12(3):545-553. doi: 10.1016/j.hrthm.2014.11.002. Epub 2014 Nov 7.
8
Prognostic importance of defibrillator shocks in patients with heart failure.
N Engl J Med. 2008 Sep 4;359(10):1009-17. doi: 10.1056/NEJMoa071098.
9
Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.
10
Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy: the importance of low-voltage scars.
J Am Coll Cardiol. 2004 May 19;43(10):1834-42. doi: 10.1016/j.jacc.2004.01.029.
Zotero 插件